Early seizures after ischemic stroke: focus on thrombolysis

CNS Spectr. 2020 Feb;25(1):101-113. doi: 10.1017/S1092852919000804.

Abstract

Introduction: Stroke is a significant underlying cause of epilepsy. Seizures due to ischemic stroke (IS) are generally categorized into early seizures (ESs) and late seizures (LSs). Seizures in thrombolysis situations may raise the possibility of other etiology than IS.

Aim: We overtook a systematic review focusing on the pathogenesis, prevalence, risk factors, detection, management, and clinical outcome of ESs in IS and in stroke/thrombolysis situations. We also collected articles focusing on the association of recombinant tissue-type plasminogen activator (rt-PA) treatment and epileptic seizures.

Results: We have identified 37 studies with 36,775 participants. ES rate was 3.8% overall in patients with IS with geographical differences. Cortical involvement, severe stroke, hemorrhagic transformation, age (<65 years), large lesion, and atrial fibrillation were the most important risk factors. Sixty-one percent of ESs were partial and 39% were general. Status epilepticus (SE) occurred in 16.3%. 73.6% had an onset within 24 h and 40% may present at the onset of stroke syndrome. Based on EEG findings seizure-like activity could be detected only in approximately 18% of ES patients. MRI diffusion-weighted imaging and multimodal brain imaging may help in the differentiation of ischemia vs. seizure. There are no specific recommendations with regard to the treatment of ES.

Conclusion: ESs are rare complications of acute stroke with substantial burden. A significant proportion can be presented at the onset of stroke requiring an extensive diagnostic workup.

Keywords: Emergency service; imaging; ischemic stroke; seizure; stroke; thrombolysis; treatment.

Publication types

  • Systematic Review

MeSH terms

  • Humans
  • Ischemic Stroke / complications*
  • Ischemic Stroke / drug therapy
  • Status Epilepticus / diagnosis
  • Status Epilepticus / epidemiology
  • Status Epilepticus / etiology*
  • Thrombolytic Therapy / adverse effects*